Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Thymitaq enters phase III for HCC

Oct. 3, 2000

Pfizer transfers anticancer compound to OSI; early trial results released

Oct. 3, 2000

MGI Pharma commences phase II liver cancer trial with irofulven

Oct. 3, 2000

NIH grants anti-Notch-1 monoclonal antibody technology to Viragen

Oct. 3, 2000

Migration-inhibitory peptides identified and investigated at Kyowa Hakko

Oct. 2, 2000

Chugai examines novel enzyme inhibitors as potential anticancer agents

Oct. 2, 2000

Beacon describes preparation and activity of improved butyric acid esters

Oct. 2, 2000

New approach to oncolytic, skin disorders based on specific inhibition of 4-hydroxylase

Oct. 2, 2000

Sigma-Tau selects new camptothecin derivative for preclinical development

Oct. 2, 2000

Northwest's prostate cancer vaccine shows favorable progress in clinical trial

Oct. 2, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...